Company intelligence / Profile preview
ScinnoHub Pharmaceutical
Chengdu, Sichuan, China
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has a broad drug pipeline mainly in preclinical development, with one lead antifibrinolytic small molecule in Phase Ib trials for bleeding/hemostasis (BT-114143). Most oncology and rare disease drugs—including Mat2A inhibitors (BT115386 for nasopharyngeal carcinoma)—are in preclinical stages. No clinical efficacy data publicly available yet.
- Therapeutic areas
- HematologyOncologyImmunologyRare Diseases
- Modalities
- Small moleculeRadiopharmaceuticals
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
The Chinese University of Hong Kong (in Mat2A research)
Beyond the preview
Go deeper on ScinnoHub Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ScinnoHub Pharmaceutical.